Industry Roundup: Prestige Brands CEO Change; P&G, Abbott, MJN Earnings
This article was originally published in The Tan Sheet
Executive Summary
Mannelly leaves, Lombardi moves up at Prestige; and Drug Facts mislabeling prompts RB recall.
You may also be interested in...
Slimmed-Down P&G To Consist Of 65 ‘Leading Brands’ By FY 2017
At the CAGNY conference Feb. 19, P&G leadership provided new insight into the company’s streamlining program, specifically where the firm will end up after selling off 100 underperforming brands in deals expected to be closed by June 30, 2016. CFO Jon Moeller listed Gillette, Pantene, Head & Shoulders and Olay among core brands that will emerge from the simplification, highlighting recent innovations and marketing initiatives that are resonating with its core audience and driving growth.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.